

Curriculum Vitae



Name (First name, middle name, surname); DR. RAJA PRAMANIK

Designation: ASSOCIATE PROFESSOR

Department: MEDICAL ONCOLOGY

Institute/University: ALL INDIA INSTITUTE OF MEDICAL SCIENCES,
NEW DELHI

Address: ROOM 216, DR. BRA-IRCH, AIIMS, NEW DELHI

PIN: 110029

Education (Post-Graduation onwards & Professional Career):

Sl No.	Institution Place	Degree Awarded	Year	Field of Study
1.	R. G. Kar Medical College, Calcutta University, Calcutta	MBBS	1999-2005	MBBS
2.	Patna Medical College, Patna, India	MD (Medicine)	2006-2009	MD (Medicine)
3.	All India Institute of Medical Sciences (AIIMS), New Delhi, India	D.M. (Medical Oncology)	2013-2016	DM (Med Oncology)

Position and Employment (Starting with the most recent employment)

Sl No. Institution	Place	Position	From (date)	To (date)
1. All India Institute Medical Sciences (AIIMS),	New Delhi, India	Senior Resident (Non-Academic) (Medical Oncology)	August 2011	June 2013
2. All India Institute of Medical Sciences (AIIMS),	New Delhi, India	Senior Resident - Non-Academic (Medical Oncology)	August 2016	2 Nov 2016
3. All India Institute of Medical Sciences (AIIMS),	New Delhi, India	Assistant Professor, Medical Oncology	3 NOV 2016	30 June 2020
4. All India Institute of Medical Sciences (AIIMS),	New Delhi, India	Associate Professor, Medical Oncology	1 JULY 2020	TILL DATE

Honors/Awards

1. Received the 2020-2021 **Fulbright-Nehru Academic and Professional Excellence Fellowship** from United States- India Education Foundation.
2. Received the prestigious **“Brigid Leventhal Merit Award”** in June 2016 at the Annual meeting of **American Society of Clinical Oncology (ASCO), in Chicago** for the best abstract in Paediatric Oncology by a fellow, as determined by the Program Committee's Paediatrics Subcommittee.
3. Received **IDEA Award (International Development and Education Award) 2016** from **American Society of Clinical Oncology, in Chicago, June 2016.**
4. Received **“Young oncologists Investigator Award” (YIA)** from the International Society of Paediatric Oncology (SIOP) for the year 2016. (Annual Meeting, Dublin, Ireland).
5. Received Travel Grant from ESMO (European Society for Medical Oncology) to attend ESMO Academy-2016, at Oxford, United Kingdom in August 2016.
6. Received the **Shakuntala Jolly Gold Medal award** for the best outgoing DM student in Medical Oncology for the year 2016 from AIIMS, New Delhi.
7. Received the **“Best thesis award” from ICON conference** (Indian cooperative oncology network) 2017.
8. Received the **“ESMO–Image of the year Award” 2015** from European Society for Medical Oncology.
9. Received Travel grant from **Department of Science & Technology** to attend the 15thInternational Myeloma Workshop in Rome, Sept 2015. (presented two posters on Engraftment syndrome and POEMS syndrome)
10. Indian Society for Medical and Paediatric Oncology (ISMPO) Gold medal exam 2016, Chennai: 2nd runner-up prize.

11. Received Travel Grant from European Society for Medical Oncology (ESMO) to attend ESMO Asia Conference in Singapore in December 2015.
12. Received Travel Grant from European Society for Medical Oncology (ESMO) to attend Preceptorship meet in Gastric Cancer in August 2015 in Brussels, Belgium.

Present Role:

I am a part of the Multidisciplinary team taking care of chemotherapy, immunotherapy and targeted therapies for Gynaecological Cancers at the All-India Institute of Medical Sciences, New Delhi. I am the Clinician-In-charge of the Familial Cancer Clinic. I am routinely involved in counselling, testing of cancer patients with suspected hereditary predisposition. We provide risk reduction strategies & comprehensive care to these high risk families, including long-term follow up of unaffected carriers. I am currently involved in formulation of Indian & Asian guidelines for HBOC and pragmatic clinical and translational research on hereditary cancers.

Publications related to HBOC:

1. **ASO Author Reflections: Germline Testing for All Patients With Breast Cancer: Has the Time Finally Come?** Mittal A, Pramanik R. *Ann Surg Oncol*. 2022 Feb;29(2):1433-1434. doi: 10.1245/s10434-021-10880-8. Epub 2021 Oct 15. PMID: 34654988
2. **Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.** Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhorawal S, Deb KS, Dhamija E, Thulkar S, Ramprasad VL, Olopade O, Pramanik R. *Ann Surg Oncol*. 2022 Feb;29(2):1423-1432. doi: 10.1245/s10434-021-10870-w. Epub 2021 Oct 2. PMID: 34601666
3. **Spectrum and management of breast cancer patients with variant of uncertain significance mutations at a tertiary care centre in North India.** Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhorawal S, Deb KS, Dhamija E, Ramprasad VL, Olopade O, Pramanik R. *Ecancermedalscience*. 2022 Aug 1;16:1434. doi: 10.3332/ecancer.2022.1434. eCollection 2022. PMID: 36200007
4. **Comprehensive Germline Genomic Profiling of Patients with Ovarian Cancer: A Cross-Sectional Study.** Pramanik R, Upadhyay A, Khurana S, Kumar L, Malik PS, Kumar S, et al. *Indian J Med Paediatr Oncol*. 2022 Aug;43(04):361–8.
5. **Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.** Malhotra H, Kowtal P, Mehra N, Pramanik R, Sarin R, Rajkumar T, Gupta S, Bapna A, Bhattacharyya GS, Gupta S, Maheshwari A, Mannan AU, Reddy Kundur R, Sekhon R, Singhal M, Smruti BK, Sp S, Suryavanshi M, Verma A. *JCO Glob Oncol*. 2020 Jul;6:991-1008. doi: 10.1200/JGO.19.00381. PMID: 32628584; PMCID: PMC7392772.

Projects related to HBOC:

Sl No.	Title of Project	Funding Agency	Amount	Date of sanction and Duration
1.	Establishment of a registry of hereditary breast and ovarian cancers and germline DNA repository at AIIMS, New Delhi	Department of Health Research, ICMR, Govt. of India	INR 2.4cr	3yr, March 2020
2.	Identifying hereditary predisposition to prostate cancers in Indian men	AIIMS Intramural fund	INR 10,00,000	2yr, June 2020
3.	Comparison of “Multigene hereditary panel testing” profiles in patients with breast cancer qualifying and not qualifying the NCCN 2018 criteria for genetic testing: a prospective study in North Indian population.	Tata Center for Development at U Chicago	50000 USD	1/4/2020

Peer-reviewed publications:

- **Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.** Pramanik R, Agarwala S, Gupta YK, Thulkar S, Vishnubhatla S, Batra A, Dhawan D, Bakhshi S. JAMA Oncol. 2017 Sep 1;3(9):1222-1227. doi: 10.1001/jamaoncol.2017.0324. PMID: 28384657
- **Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.** Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhorival S, Deb KS, Dhamija E, Thulkar S, Ramprasad VL, Olopade O, Pramanik R. Ann Surg Oncol. 2022 Feb;29(2):1423-1432. doi: 10.1245/s10434-021-10870-w. Epub 2021 Oct 2. PMID: 34601666
- **Spectrum and management of breast cancer patients with variant of uncertain significance mutations at a tertiary care centre in North India.** Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhorival S, Deb KS, Dhamija E, Ramprasad VL, Olopade O, Pramanik R. Ecancermedalscience. 2022 Aug 1;16:1434. doi: 10.3332/ecancer.2022.1434. eCollection 2022. PMID: 36200007
- **A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).** Baa AK, Sharma A, Bhaskar S, Biswas A, JeeBharti S, Thakar A, Kumar R, Pramanik R. Ecancermedalscience. 2022 Sep 29;16:1451. doi: 10.3332/ecancer.2022.1451. eCollection 2022. PMID: 36405947
- **Evaluation of Vascular Endothelial Growth Factor (VEGF) and Thrombospondin-1 as Biomarkers of Metronomic Chemotherapy in Progressive Pediatric Solid Malignancies.** Pramanik R, Tyagi A, Agarwala S, Vishnubhatla S, Dhawan D, Bakhshi S. Indian Pediatr. 2020 Jun 15;57(6):508-511. Epub 2020 Mar 12. PMID: 32221052
- **Quality of life in paediatric solid tumours: a randomised study of metronomic chemotherapy versus placebo.** Pramanik R, Agarwala S, Sreenivas V, Dhawan D, Bakhshi S. BMJ Support Palliat Care. 2021 Jan 19;bmjspcare-2020-002731. doi: 10.1136/bmjspcare-2020-002731. PMID: 33468507
- **Real World Presentation and Treatment Outcomes with a Predominant Induction Chemotherapy Based Approach in Nasopharyngeal Carcinoma: A Sixteen Year Report from a Teaching Hospital in India.** Gogi R, Sharma A, Sharma A, Mohanti BK, Pramanik

- R, Bhasker S, Biswas A, Thakar A, Singh AC, Sikka K, Kumar R, Thulkar S, Bahadur S. *Cancer Invest.* 2022 Nov 17;1-9. doi: 10.1080/07357907.2022.2141771. PMID: 36305837
- **Modified Protocol of Nivolumab in Relapsed/Refractory Hodgkin Lymphoma: A Brief Communication of Real World Data.** Pathak N, Pramanik R, Bakhshi S, Kumar A, Sharma MC, Shamim SA, Kumar S, Thulkar S, Sharma A. *J Immunother.* 2022 Jun 1;45(5):239-242. doi: 10.1097/CJI.0000000000000411. Epub 2022 Apr 11. PMID: 35404324
 - **Myeloid Sarcoma Predicts Superior Outcome in Pediatric AML; Can Cytogenetics Solve the Puzzle?** Pramanik R, Tyagi A, Chopra A, Kumar A, Vishnubhatla S, Bakhshi S.
 - *Clin Lymphoma Myeloma Leuk.* 2018 Jun;18(6):e249-e254. doi: 10.1016/j.clml.2018.03.013. Epub 2018 Mar 31. PMID: 29680411
 - **POEMS Syndrome: Indian Experience From a Tertiary-Care Institute.** Pramanik R, Sharma A, Sharma A, Gogia A, Sahoo RK, Malik PS, Padma MV, Cyriac SL, Kumar L. *Clin Lymphoma Myeloma Leuk.* 2019 Sep;19(9):e536-e544. doi: 10.1016/j.clml.2019.05.018. Epub 2019 May 29. PMID: 31262669
 - **Capecitabine Maintenance in Metastatic Nasopharyngeal Carcinoma.** S G N, Sharma A, Pramanik R. *JAMA Oncol.* 2022 Aug 1;8(8):1224. doi: 10.1001/jamaoncol.2022.2065. PMID: 35771563
 - **Metronomic therapy in pediatric oncology: A snapshot.** Pramanik R, Bakhshi S. *Pediatr Blood Cancer.* 2019 Sep;66(9):e27811. doi: 10.1002/pbc.27811. Epub 2019 Jun 17. PMID: 31207063
 - **Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging.** Kumar L, Pramanik R, Kumar S, Bhatla N, Malik S. *Best Pract Res Clin Obstet Gynaecol.* 2015 Aug;29(6):790-801. doi: 10.1016/j.bpobgyn.2015.02.008. Epub 2015 Mar 6. PMID: 25840650
 - **Oncotype DX: Where Does It Stand in India?** Batra A, Patel A, Gupta VG, Mehta P, Tsvngk T, Biswas B, Pramanik R, Das CK, Srivastava P. *J Glob Oncol.* 2019 Jul;5:1-2. doi: 10.1200/JGO.19.00151. PMID: 31310569
 - **Oral metronomic therapy in head and neck cancer.** Pramanik R, Sharma A, Kumar A. *Lancet Glob Health.* 2021 Jan;9(1):e19. doi: 10.1016/S2214-109X(20)30461-7. PMID: 33338454
 - **Second-line FOLFOX chemotherapy for advanced biliary tract cancer.** Pramanik R, Sharma A, Kumar A. *Lancet Oncol.* 2021 Jul;22(7):e287. doi: 10.1016/S1470-2045(21)00280-1. PMID: 34197750
 - **Extra-nasal NK/T-cell lymphoma: A rare case with a rarer presentation.** Kumar C, Jain G, Gupta A, Pramanik R, Chopra A. *Cytopathology.* 2022 Jul;33(4):518-521. doi: 10.1111/cyt.13095. Epub 2022 Feb 19. PMID: 34995382
 - **Neutropenia due to palbociclib: A word of caution?** Pramanik R, Sahoo RK, Gogia A. *Indian J Med Paediatr Oncol.* 2016 Jul-Sep;37(3):206. doi: 10.4103/0971-5851.190351. PMID: 27688617
 - **Clinical Benefit of Comprehensive Genomic Profiling for Advanced Cancers in India.** Mathew A, Joseph S, Bobby J, Benny S, Veedu J, Rajappa S, Rohatgi N, Sirohi B, Jain R, Agarwala V, Shukla DK, Mehta A, Pramanik R, Talwar V, Maka V, Raut N. *JCO Glob Oncol.* 2022 Mar;8:e2100421. doi: 10.1200/GO.21.00421. PMID: 35404667

- **Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors-Reply.** Pramanik R, Vishnubhatla S, Bakhshi S. *JAMA Oncol.* 2018 May 1;4(5):744. doi: 10.1001/jamaoncol.2017.4891. PMID: 29372244
- **ASO Author Reflections: Germline Testing for All Patients With Breast Cancer: Has the Time Finally Come?** Mittal A, Pramanik R. *Ann Surg Oncol.* 2022 Feb;29(2):1433-1434. doi: 10.1245/s10434-021-10880-8. Epub 2021 Oct 15. PMID: 34654988
- **Cell-free EBV DNA as a biomarker during clinical management of nasopharyngeal carcinoma in a nonendemic region.** Pramanik R, Arora S, Sharma P, Biswas A, Nayak B, Thakar A, Sharma A, Ghose S. *J Med Virol.* 2022 Feb;94(2):720-728. doi: 10.1002/jmv.27440. Epub 2021 Nov 15. PMID: 34750844
- **Characteristics & outcomes of cancer patients with COVID-19: A multicentre retrospective study from India.** Kumar A, Baghmar S, Mehta P, Tiwari P, Kumar L, Bakhshi S, Agarwal A, Gupta I, Trikha A, Bhatnagar S, Gogia A, Malik PS, Sahoo RK, Rastogi S, Pramanik R, Batra A, Pushpam D, Sharma CK, Sharma V, Kataria B, Goyal K, Samaga S, Bothra SJ, Sharma A. *Indian J Med Res.* 2022 May-Jun;155(5&6):546-553. doi: 10.4103/ijmr.ijmr_1703_21. PMID: 36348601
- **Platelet Normalized Serum Vascular Endothelial Growth Factor Levels in Progressive Pediatric Solid Malignancies: Authors' Reply.** Pramanik R, Bakhshi S. *Indian Pediatr.* 2020 Dec 15;57(12):1188-1189. doi: 10.1007/s13312-020-2082-5. PMID: 33318333
- **Expression of mitochondrial genes predicts survival in pediatric acute myeloid leukemia.** Tyagi A, Pramanik R, Bakhshi R, Singh A, Vishnubhatla S, Bakhshi S. *Int J Hematol.* 2019 Aug;110(2):205-212. doi: 10.1007/s12185-019-02666-2. Epub 2019 May 22. PMID: 31119613
- **Cytogenetic Profiles of 472 Indian Children with Acute Myeloid Leukemia.** Tyagi A, Pramanik R, Chaudhary S, Chopra A, Bakhshi S. *Indian Pediatr.* 2018 Jun 15;55(6):469-473. PMID: 29978812
- **Long-Term Survivors of Metastatic Colorectal Cancer: A Tertiary Care Centre Experience.** Sharma A, Sharma A, Sharma V, Kumar S, Kumar A, Deo S, Pathy S, Shukla NK, Pramanik R, Raina V, Thulkar S, Kumar R, Mohanti BK. *South Asian J Cancer.* 2021 Apr;10(2):87-91. doi: 10.1055/s-0041-1736343. Epub 2021 Sep 23. PMID: 34568221
- **Chronic lymphocytic leukemia with massive ascites: An unusual presenting manifestation.** Gogia A, Mehta P, Pramanik R, Gupta R. *South Asian J Cancer.* 2014 Oct;3(4):235-6. doi: 10.4103/2278-330X.142999. PMID: 25422818
- **Non-immunological biomarkers for assessment of villous abnormalities in patients with celiac disease.** Singh A, Verma AK, Das P, Prakash S, Pramanik R, Nayak B, Datta Gupta S, Sreenivas V, Kumar L, Ahuja V, Makharia GK. *J Gastroenterol Hepatol.* 2020 Mar;35(3):438-445. doi: 10.1111/jgh.14852. Epub 2019 Oct 30. PMID: 31498492
- **Genetic Landscape of Mitochondrial Regulatory Region in Pediatric Acute Myeloid Leukemia: Changes from Diagnosis to Relapse.** Tyagi A, Pramanik R, Bakhshi R, Vishnubhatla S, Bakhshi S. *J Pediatr Genet.* 2019 Dec;8(4):193-197. doi: 10.1055/s-0039-1696976. Epub 2019 Sep 12. PMID: 31687256
- **Engraftment Syndrome: A Retrospective Analysis of the Experience at a Tertiary Care Institute.** Pramanik R, Kancharla H, Bakhshi S, Sharma A, Gogia A, Malik P, Sahoo RK,

Batra A, Thulkar S, Kumar L. Clin Hematol Int. 2019 May 24;1(2):114-119. doi: 10.2991/chi.d.190504.001. eCollection 2019 Jun. PMID: 34595419

- **Apoptosis: A biomarker of high-risk phenotype in pediatric acute myeloid leukemia?** Tyagi A, Pramanik R, Bakhshi R, Vishnubhatla S, Bakhshi S. Int J Lab Hematol. 2019 Feb;41(1):141-147. doi: 10.1111/ijlh.12939. Epub 2018 Nov 1. PMID: 30383325
- **Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets.** Patel A, Tannock IF, Srivastava P, Biswas B, Gupta VG, Batra A, Bhethanabhotla S, Pramanik R, Mahindru S, Tilak T, Das CK, Mehta P. JCO Glob Oncol. 2020 Mar;6:382-386. doi: 10.1200/JGO.19.00341. PMID: 32125899
- **Oral Cancer in the Indian Subcontinent-Survival Outcomes and Risk Factors with Primary Surgery.** Thakar A, Thakur R, Kakkar A, Malhotra RK, Singh CA, Sikka K, Kumar R, Pramanik R, Biswas A, Bhalla AS, Bhaskar S, Sharma A. Laryngoscope. 2021 Oct;131(10):2254-2261. doi: 10.1002/lary.29537. Epub 2021 Apr 1. PMID: 33797083
- **Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report From A Tertiary Care Center in India.** Kumar S, Sharma A, Pramanik R, Pathak N, Gogia A, Kumar A, Kayal S, Sharma V, Sahoo RK, Thulkar S, Sharma MC, Gupta R, Mallick S, Thomas M, Raina V. JCO Glob Oncol. 2022 May;8:e2100383. doi: 10.1200/GO.21.00383. PMID: 35561291
- **Efficacy and Safety of Percutaneous Radiological Gastrostomy (PRG) as a Rescue Measure for Enteral Feeding in Patients with Advanced Head, Neck, and Upper Digestive Malignancies.** Kumar M, Chahal A, Malla S, Bharti SG, Kumar S, Biswas A, Sahoo R, Pramanik R, Pathy S, Bhaskar S, Chandrashekhara SH, Sreenivas V, Thulkar S. Indian J Radiol Imaging. 2022 Oct 31;32(4):471-478. doi: 10.1055/s-0042-1750154. eCollection 2022 Dec. PMID: 36451943
- **Isolated Lymph Node Amyloidosis: Response Assessment to Chemotherapy on Serial 18F-FDG PET/CT Scans.** Tripathy S, Bharadwaj M, Prakash S, Pramanik R, Mittal A, Shamim SA. Clin Nucl Med. 2020 Sep;45(9):705-706. doi: 10.1097/RLU.0000000000003156.
 - PMID: 32604112
- **Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient.** Prakash VS, Malik PS, Sahoo RK, Pramanik R, Choudhary P, Varshney AN, Kumar L. Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):44-51. doi: 10.1016/j.clml.2021.07.030. Epub 2021 Aug 2. PMID: 34452863
- **Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).** Santhosh A, Kumar A, Pramanik R, Gogia A, Prasad CP, Gupta I, Gupta N, Cheung WY, Pandey RM, Sharma A, Batra A. Trials. 2022 May 19;23(1):420. doi: 10.1186/s13063-022-06353-2. PMID: 35590388
- **Prognostic impact of mitochondrial DNA D-loop variations in pediatric acute myeloid leukemia.** Tyagi A, Pramanik R, Vishnubhatla S, Bakhshi R, Bakhshi S. Oncotarget. 2019 Feb 12;10(13):1334-1343. doi: 10.18632/oncotarget.26665. eCollection 2019 Feb 12. PMID: 30863493

- **Complete response after autologous stem cell transplant in multiple myeloma.** Kumar L, Iqbal N, Mookerjee A, Verma RK, Sharma OD, Batra A, Pramanik R, Gupta R. *Cancer Med*. 2014 Aug;3(4):939-46. doi: 10.1002/cam4.257. Epub 2014 Apr 29. PMID: 24777883
- **Metastatic Primary Angiosarcoma of the Breast: Can We Tame It the Metronomic Way.** Pramanik R, Gogia A, Malik PS, Gogi R. *Indian J Med Paediatr Oncol*. 2017 Apr-Jun;38(2):228-231. doi: 10.4103/ijmpo.ijmpo_156_16. PMID: 28900339
- **SMARCB1 (INI1)-deficient sinonasal carcinoma: a series of 13 cases with assessment of histologic patterns.** Kakkar A, Antony VM, Pramanik R, Sakthivel P, Singh CA, Jain D. *Hum Pathol*. 2019 Jan;83:59-67. doi: 10.1016/j.humpath.2018.08.008. Epub 2018 Aug 16. PMID: 30120966
- **Squamous cell carcinoma as a somatic-type malignancy in an extragonadal immature teratoma of the sinonasal region.** Sakthivel P, Kumar Irugu DV, Kakkar A, Kaur K, Jain S, Pramanik R, Biswas A. *Int J Pediatr Otorhinolaryngol*. 2019 Nov;126:109639. doi: 10.1016/j.ijporl.2019.109639. Epub 2019 Aug 12. PMID: 31442873
- **Solid pseudopapillary neoplasm of the ovary with metastases to the omentum and regional lymph nodes.** Gahlot GP, Mridha AR, Sable M, Sharma MC, Pramanik R, Kumar L. *Indian J Pathol Microbiol*. 2016 Jul-Sep;59(3):348-50. doi: 10.4103/0377-4929.188107. PMID: 27510674
- **Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study.** Sharma A, Pramanik R, Kumar A, Pathy S, Kumar S, Bhorawal S, Thulkar S, Dash NR, Pal S, Choudhary P, Pawar S, Kumar R, Gupta G. *JCO Glob Oncol*. 2021 Jun;7:820-826. doi: 10.1200/GO.20.00657. PMID: 34086477
- **Pattern of mitochondrial D-loop variations and their relation with mitochondrial encoded genes in pediatric acute myeloid leukemia.** Tyagi A, Pramanik R, Vishnubhatla S, Ali S, Bakhshi R, Chopra A, Singh A, Bakhshi S. *Mutat Res*. 2018 Jul;810:13-18. doi: 10.1016/j.mrfmmm.2018.05.002. Epub 2018 May 24. PMID: 29883862
- **Ewing Sarcoma of Urinary Bladder Showing EWSR1 Rearrangement on FISH Analysis and Unique Response to Chemotherapy.** Vallonthaiel AG, Kaur K, Jain D, Singh G, Tiwari D, Pramanik R, Singh P, Sharma MC. *Clin Genitourin Cancer*. 2016 Apr;14(2):e183-6. doi: 10.1016/j.clgc.2015.11.001. Epub 2015 Nov 11. PMID: 26684812
- **Comparison of treatment response assessed by 18F-FDG PET/CT with the histopathological response using tumor regression grading on surgically resected specimen following neoadjuvant chemotherapy in squamous cell carcinoma of esophagus.** Kumar N, Deo S, Bhorawal S, Sharma A, Pramanik R, Kumar R, Das P, Arora S, Kumar S. *Nucl Med Commun*. 2021 Aug 1;42(8):928-934. doi: 10.1097/MNM.0000000000001413. PMID: 33795613
- **Isolated breast relapse mimicking breast cancer in elderly patient with acute lymphoblastic leukemia.** Gogia A, Mehta P, Pramanik R, Kumar R. *Turk J Haematol*. 2014 Jun;31(2):203-4. doi: 10.4274/tjh.2013.0270. Epub 2014 Jun 10. PMID: 25035685

- **Personal Protective Equipment (PPE) use is Associated with Physical and Neurological Dysfunction Among Health Care Workers- Survey Report During the Covid-19 Pandemic.** Patel M, Pramanik R, Patel A. J Assoc Physicians India. 2021 Jun;69(6):11-12. PMID: 34472795
- Ramachandran A, Bhalla D, Rangarajan K, Pramanik R, Banerjee S, Arora C. **Building and evaluating an artificial intelligence algorithm: A practical guide for practicing oncologists. Artificial Intelligence in Cancer.** 2022 Jul 28;3(3):42-53.
- Ray MD, Deo SVS, Pramanik R, Premanand N. **An intensive audit on 250 patients of advanced ovarian cancer to improve quality of care in a tertiary referral oncology centre in India.** Int J Reprod Contracept Obstet Gynecol 2022;11:2723-8.
- Jain S, Goswami A, Lone MR, Ramteke P, Pramanik R, Dhawan R, Kumar L, Mallick S. **Follicular Helper T-Cell-derived Nodal Lymphomas: Study of Histomorphologic, Immunophenotypic, Clinical, and RHOA G17V Mutational Profile.** Appl Immunohistochem Mol Morphol. 2023 Mar 1;31(3):172-180. doi: 10.1097/PAI.0000000000001105. Epub 2023 Feb 20. PMID: 36806188.
- Pramanik R, Upadhyay A, Khurana S, Kumar L, Malik PS, Kumar S, Ray MD, Deo SV, Gupta R, Thakral D, Thulkar S. **Comprehensive Germline Genomic Profiling of Patients with Ovarian Cancer: A Cross-Sectional Study.** Indian Journal of Medical and Paediatric Oncology. 2022 Aug;43(04):361-8.
- Kumar M, Chahal A, Malla S, Bharti SG, Kumar S, Biswas A, Sahoo R, Pramanik R, Pathy S, Bhaskar S, Chandrashekhara SH. **Efficacy and Safety of Percutaneous Radiological Gastrostomy (PRG) as a Rescue Measure for Enteral Feeding in Patients with Advanced Head, Neck, and Upper Digestive Malignancies.** Indian Journal of Radiology and Imaging. 2022 Dec;32(04):471-8.
- Deo SV, Pramanik R, Chaturvedi M, Nath A, Ghosh J, Das Majumdar SK, Salins N, Kadayaprath G, Garg PK, Chaturvedi A, Mathur S. **Telemedicine and cancer care in India: promises, opportunities and caveats.** Future Science OA. 2022 Dec(0):FSO821.

Chapters in Books:

1. **Essentials of Rhinology.** Springer ISBN:978-981-33-6284-0 Chapter: Radiotherapy, Chemotherapy & Quality of Life Devnani B, Bhasker S, Pramanik R, SPVladmani, Mani S
2. Cancer Screening. Sharma A, Pramanik R. **API Textbook of Medicine**, 11th Edition
3. Pramanik, Raja, and Aparna Sharma. "Carcinoid Crisis in ICU." In *Onco-critical Care: An Evidence-based Approach*, pp. 263-269. Singapore: Springer Nature Singapore, 2022.
4. Pramanik, Raja, Raghav Gupta, Praneeth Suvvari, and Seema Mishra. "Management of Complications and Toxicities Related to Chemotherapy in ICU." In *Onco-critical Care: An Evidence-based Approach*, pp. 279-291. Singapore: Springer Nature Singapore, 2022.

Research Support; Ongoing Research Projects as Principal Investigator

Sl No.	Title of Project	Funding Agency	Amount	Date of sanction and Duration
1	Establishment of a registry of hereditary breast and ovarian cancers and germline DNA repository at AIIMS, New Delhi	Department of Health Research, ICMR, Govt. of India	INR 2.4cr	3yr, March 2020
2	Identifying hereditary predisposition to prostate cancers in Indian men	AIIMS Intramural fund	INR 10,00,000	2yr, June 2020
3.	Assessment of cfDNA as a biomarker for common gastrointestinal cancers	AIIMS Intramural fund interdepartmental Collaboratory	INR 20,00,000	2yr 2021

Completed Research Projects (as Principal Investigator)

Sl No.	Title of Project	Funding Agency	Amount	Date of completion
1	Comparison of “Multigene hereditary panel testing” profiles in patients with breast cancer qualifying and not qualifying the NCCN 2018 criteria for genetic testing: a prospective study in North Indian population.	Tata Center for Development at U Chicago	50000 USD	1/4/2020
2	Expression and Significance of Notch signalling-associated proteins, Notch 1, Notch 2, Notch 3, Hes1 and p21 in oesophageal squamous cell carcinoma: A retrospective Study.	AIIMS Intramural fund	INR 1000000	1/4/2018
3	“EMF (Erlotinib/Methotrexate/5-FU) regimen as an efficacious therapy in unresectable or recurrent/metastatic Head Neck Squamous cell carcinoma after platinum failure: Investigator initiated, single-arm, phase II trial”			3yr, June 2019
4	Assessment of Sexual health related problems in cancer patients undergoing chemotherapy.			3yr, Dec, 2022

Research Support: Research Projects as Co- Investigator

Sl No.	Title of Project
1.	Neoadjuvant chemotherapy followed by Surgery versus Surgery followed by adjuvant chemotherapy for resectable Gastric adenocarcinoma- 2x2 Factorial Phase 3 Multicentric Randomized Controlled trial
2.	A Phase 3, Double- Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma (QPT-ORE-005).
3.	A Prospective study to determine the efficacy of Positron Emission Tomography-Computed Tomography (18F- FDG PET-CT) scan in detecting residual disease in Locally Advanced Head & Neck Squamous Cell Carcinoma managed with primary Chemo-Radiation Therapy and its comparison with CECT
4.	Analysis of voice outcomes after radiation or chemo-radiation in carcinoma larynx and the effect of N- acetyl cysteine on voice parameters
5.	Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
6.	Olanzapine versus Fosaprepitant for prevention of chemotherapy induced nausea and vomiting in patients receiving carboplatin (AUC>4) containing chemotherapy: a randomized, double blinded, placebo controlled trial.

7.	Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy versus long-course chemoradiotherapy: comparison of overall response rates.
8.	A Randomized controlled trial to assess the effectiveness of nurse led navigation clinic in adult oncology outpatient unit on patient satisfaction, treatment adherence and psychological burden among cancer patients in DR B.R.A IRCH, AIIMS, New Delhi.
9.	A randomized controlled trial to assess the effectiveness of chewing gum on reducing incidence and severity of chemotherapy induced oral mucositis and quality of life among patients receiving conventional muco-toxic chemotherapy
10.	A phase-III randomised controlled study comparing xerostomia after tuba rial salivary gland sparing IMRT versus standard IMRT in patients with locally advanced oropharyngeal squamous cell carcinoma
11.	Concurrent chemotherapy and external radiation therapy: An open label non-inferiority phase III randomized controlled trial of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma: CONCERT trial
12.	Adjuvant Chemotherapy or Chemo-radiation in Gall Bladder Cancer: A Phase III Randomized Controlled Study (ACCeLeRate trial)
13.	Efficacy and Safety of Percutaneous Radiological Gastrostomy (PRG) as a Rescue Measure for Enteral Feeding in Patients with Advanced Head, Neck, and Upper Digestive Malignancies.
14.	Randomized control trial comparing the pain scores in carcinoma gall bladder patients undergoing percutaneous transhepatic biliary drainage under transversus abdominis plane block versus without the transversus abdominis plane block
15.	Evaluation of germline genomic profile of ovarian cancers in India.
16.	A phase II study to evaluate the efficacy of cisplatin and gemcitabine based neo-adjuvant chemotherapy followed by dysphagia optimized intensity modulated radiotherapy with concomitant cisplatin and correlation of clinical outcome with serial plasma Epstein Barr virus DNA titre in patients with locally advanced nasopharyngeal carcinoma
17.	A single arm phase II study of single agent Pemetrexed in Platinum Resistant/Refractory Epithelial Ovarian or Primary Peritoneal Cancer
18.	Hypofractionated palliative radiotherapy using “quad shot regimen” with concurrent cisplatin in patients with locally advanced head and neck squamous cell carcinoma. unsuitable for curative treatment
19.	Efficacy of Neoadjuvant chemotherapy in carcinoma Esophagus-A pilot study comparing Cisplatin + 5 FU with Paclitaxel + Carboplatin
20.	Three arm phase II/III randomised controlled trial in patients with metaststic/unresectable Gall bladder cancer with poor performance status- Best supportive care/Erlotinib /Capecitabine.
21.	Efficacy of Neoadjuvant chemotherapy protocol in locally advanced, carcinoma oral cavity- A randomised, pilot study comparing Cisplatin+5-FU with Paclitaxel+Carboplatin
22.	Prospective study of in person versus online cancer genetic counselling and ambispective evaluation of patients undergoing risk reducing surgery.

Memberships of Professional Bodies

1. Member: European Society for Medical Oncology, (ESMO). (ID: 315295)
2. Member: American Society of Clinical Oncology, (ASCO). (# 567426)
3. Member: Indian Society of Medical and Paediatric Oncology, (ISMPO)
4. Member: Paediatric Haemato-Oncology chapter of Indian Academy of Paediatrics (PHO-IAP)
5. Member: Immuno-Oncology Society of India (IOSI)

Workshops and Conferences conducted:

1. Organising secretary: Indian Cancer Genetics and Genomics Conference, 21-22nd Nov 2020, Hybrid-Virtual, AIIMS, New Delhi organised by Research and Education society of Medical Oncology (RESMO), Department of Medical oncology, INDO-UK Genetic Education Forum
2. Organising secretary: Onco-emergency Summit, 9th Nov 2019, AIIMS, New Delhi.
3. Organised and conducted the “Breast Cancer Genetics workshop” at ABSICON (Association of breast surgeons of India conference), 9th Nov 2018, AIIMS, New Delhi.

Community Services

1. As a part of the team of doctors from AIIMS, New Delhi, I contributed to the medical camp for Tibetan refugees organised by Patient Care Trust (PCT) at Dharamshala, Himachal Pradesh 19-20 June 2019 and again by PCT and Loseling Monastery in Mundgod, Hubli from 11Jan to 16 Jan 2023.
2. **Public awareness lecture on HBOC** under aegis of Oncology Nurses association of India, ONAI, Saket bar association, (30th April, 2019).

Expert Committee Member:

1. Member of Expert committee for preparing “Genetic Counselling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Paediatric Oncology”.
2. Member of Asian society for Gynecological Oncology (ASGO) Special Task Force on Personalized Medicine for development of Asian guidelines on genetic testing for Gynaecological cancers.
3. Member of sub-committee formed by ICMR (Indian Council of Medical Research) for development of consensus guidelines on Precision medicine in cancer.
4. Member of sub-committee formed by ICMR (Indian Council of Medical Research) for development of consensus guidelines on Telemedicine in cancer.
5. Faculty for NICPR-ECHO-ICMR- National Institute of Cancer Prevention And Research, Noida, for Online Advanced Cancer Screening Training Program for Dentists (ACSTP) since 2018.

Signature of Investigator:

Date: 18 March 2023